Enjoy complimentary customisation on priority with our Enterprise License!
Report on How AI is Driving Market Transformation 
The RNA based therapeutics market size is forecast to increase by USD 1.26 billion at a CAGR of 5.54% between 2023 and 2028. The market is experiencing significant growth, driven by several key factors. One of the primary growth drivers is the increasing investment and funding in this field, as pharmaceutical companies and venture capitalists recognize the potential of RNA therapies to address previously untreatable diseases. Another trend is the rising number of collaborations and partnerships between industry players, academic institutions, and government organizations, aimed at advancing RNA-based research and bringing new therapies to market. However, the high cost of developing RNA-based therapeutics remains a significant challenge, as these complex molecules require sophisticated manufacturing processes and specialized delivery systems. Despite these challenges, the market is expected to continue growing, fueled by the promise of RNA therapies to revolutionize the treatment of genetic diseases and other conditions.
The RNA-based therapeutics market encompasses the development, production, and application of RNA-based medicines for treating various diseases. The market scope includes oncology pharmaceuticals for cancer treatment, infectious diseases, geriatric population, and neurodegenerative disorders. Key technologies involve RNA interference, drug delivery, and gene delivery. RNA types include small interfering RNAs, microRNAs, and messenger ribonucleic acid. Regulatory requirements and personalized medicine are significant factors influencing market growth. HTS and molecular diagnostics facilitate research and academic laboratories and hospitals & diagnostic laboratories in advancing RNA-based therapies. Applications include chronic illnesses, vaccine types, and therapeutic devices. Immunologic characteristics, T-cell responses, and B-cell responses are crucial in understanding RNA-based therapeutics' pharmacologic frontiers. Rare conditions and heart disease are emerging areas of focus in the RNA-based therapeutics market.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion " for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The market share growth by mRNA therapeutics segment will be significant during the forecast period. RNA-based therapies have emerged as a promising frontier in pharmaceuticals, particularly in the fields of oncology, infectious diseases, and neurodegenerative disorders. These therapies, which include RNA interference (RNAi), gene delivery, and RNA vaccines, offer innovative solutions for various chronic conditions and rare diseases. RNAi treatment targets specific genes to inhibit protein expression, making it a potential therapy for various diseases, including cancer, heart disease, and pulmonary diseases.
Get a glance at the market share of various regions Download the PDF Sample
The Intravenous (IV) segment in the global market has steadily grown from USD 1.25 billion in 2018. Biopharmaceutical and biotechnological companies are investing heavily in RNA therapeutics, with a focus on regulatory requirements and drug delivery systems. Personalized medicine and molecular diagnostics are also driving the growth of this market, with HTS and research & academic laboratories playing a crucial role in the development of new RNA-based therapies. MicroRNAs, a type of non-coding RNA, are gaining attention for their potential in therapeutic applications. RNA vaccines are another area of focus, with development ongoing for various vaccine types, including mRNA and siRNA vaccines. Comparison of RNAi treatment and other therapeutic classes is an active area of research, with studies examining the immunologic characteristics of T-cell and B-cell responses. Regulating authorities and government bodies are closely monitoring the development of RNA-based therapies, with an emphasis on safety and efficacy. Innovative products in this field, such as therapeutic devices and rare condition treatments, are expected to drive the growth of the RNA therapeutics market in the coming years. Chronic illnesses, including cancer clinical studies, are a significant application area for these therapies, with potential for significant impact on patient outcomes.
For more insights on the market share of various regions Download PDF Sample now!
Europe is estimated to contribute 36% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. RNA-based therapeutics refer to treatments that utilize RNA molecules to target and modify disease-causing genes or proteins. This market encompasses various applications, including vaccine development, therapeutic ribozymes, small interfering RNAs (siRNAs), aptamers, and targeted therapy. Technological advances in RNAi Interference Technology, Smart Technology, and Antisense Technology have significantly contributed to the growth of this sector. Biopharmaceutical drugs based on RNA are increasingly being used to address disease targets in HIV, genetic disorders, and chronic diseases such as cancer. Public-private investments have been instrumental in the development of these therapies, with notable progress in oncology.
Moreover, the chronic disease burden and escalating healthcare spending have created a conducive environment for enabling and enabled technologies in RNA-based therapeutics. Key applications include HIV, genetic disorders, oncology, and vaccines. HIV continues to pose a significant health challenge, with ongoing research focusing on RNA-based therapeutics for its treatment. Genetic disorders, such as cystic fibrosis and Huntington's disease, are also being targeted using RNA-based therapeutics. In oncology, RNA-based therapeutics offer potential for targeted therapy, with siRNAs and aptamers being used to silence specific genes or proteins involved in cancer development and progression. The advancements in RNA-based therapeutics are poised to revolutionize the healthcare landscape, offering new hope for patients suffering from various diseases.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Growing investment and funding in RNA based therapeutics is notably driving market growth. The market is experiencing substantial growth due to escalating investments in research and development from various sectors. This trend is driven by the immense potential of RNA technologies in transforming the pharmaceutical landscape, particularly in areas such as oncology, infectious diseases, neurodegenerative disorders, and chronic conditions. Government bodies, including the U.S. National Science Foundation (NSF), are significantly contributing to this growth through funding initiatives. For instance, the NSF's Molecular Foundations for Biotechnology (MFB) program has allocated over USD12.7 million to nine research teams, focusing on exploring the untapped potential of ribonucleic acid (RNA) for diverse applications, including disease prevention in crops, gene delivery, and cancer therapies.
Furthermore, RNA-based therapeutics encompass various classes, such as RNA interference, RNA vaccines, and RNA-based drugs. These innovative products hold promise for treating a wide range of conditions, from rare diseases and heart disease to cancer and pulmonary diseases. RNAi treatment comparison, molecular diagnostics, and personalized medicine are also gaining traction in research and academic laboratories, hospitals & diagnostic laboratories, and biopharmaceutical and biotechnological companies. Key therapeutic areas include immunologic characteristics, vaccine types, and therapeutic devices. Medical studies continue to explore the intricacies of RNA-based therapies, including protein expression, T-cell responses, and B-cell responses, to optimize their efficacy and safety. RNA vaccine development is a significant area of focus, with messenger ribonucleic acid (mRNA) vaccines demonstrating promising results in cancer clinical studies. Overall, the market is poised to revolutionize the pharmacologic frontiers, offering hope for the treatment of various diseases and disorders. Thus, such factors are driving the growth of the market during the forecast period.
Increasing collaborations and partnerships is the key trend in the market. RNA-based therapies are gaining significant attention in the pharmaceutical industry due to their potential to address various medical conditions, including oncology, infectious diseases, neurodegenerative disorders, and chronic conditions. The collaborative efforts of biopharmaceutical and biotechnological companies, research institutions, hospitals, and regulatory bodies are propelling the advancements in this field. For instance, in February 2023, Tevard Biosciences and Vertex Pharmaceuticals joined forces to develop novel tRNA-based therapies for Duchenne Muscular Dystrophy, combining Tevard's research capabilities and Vertex's therapeutic expertise. Similarly, Esperovax and Gingko Bioworks entered into a partnership in January 2023 to create circular RNA therapeutics for colorectal cancer, focusing on utilizing advanced technologies to progress cancer treatment. These collaborations demonstrate the importance of strategic alliances in driving innovation and addressing complex medical challenges.
Furthermore, RNA-based therapies encompass various classes, such as RNA interference, gene delivery, and RNA vaccines, which are being explored for treating rare conditions, heart disease, cancer, and pulmonary diseases. Medical studies and clinical trials are ongoing to evaluate the therapeutic potential of RNA-based treatments, including RNAi treatment comparison, RNA vaccine development, and RNA-based therapies for gene expression modulation and immunologic characteristics. As the field evolves, innovative products and therapeutic devices are emerging, offering new possibilities for personalized medicine and addressing pharmacologic frontiers. Regulatory requirements and molecular diagnostics play a crucial role in ensuring the safety and efficacy of these novel therapies. MicroRNAs, protein expression, T-cell responses, and B-cell responses are among the areas of active research in RNA-based therapies. Thus, such trends will shape the growth of the market during the forecast period.
High cost of developing RNA based therapeutics is the major challenge that affects the growth of the market. RNA-based therapeutics, including RNA interference (RNAi) and messenger ribonucleic acid (mRNA) vaccines, have emerged as innovative solutions for addressing various medical conditions, particularly in the fields of oncology pharmaceuticals, infectious diseases, neurodegenerative disorders, and chronic conditions. These therapies offer the potential to modify gene expression, deliver drugs, and enhance protein expression, making them valuable tools for treating rare conditions and complex diseases. The development of RNA-based therapeutics, however, comes with significant challenges, primarily due to their high cost. For instance, RNAi treatment for rare genetic disorders can cost upwards of USD 1 million per patient. mRNA vaccines, such as those used for COVID-19, have also faced production challenges due to their complex manufacturing processes. Despite these challenges, the potential benefits of RNA-based therapies are substantial. In oncology, RNAi treatments have shown promise in cancer clinical studies by targeting specific genes, while mRNA vaccines have demonstrated impressive immunologic characteristics, eliciting both T-cell and B-cell responses. RNA-based therapies are also being explored for the treatment of keloids and various chronic illnesses.
Furthermore, biotechnological and biopharmaceutical companies, hospitals and diagnostic laboratories, research institutions, and government bodies are collaborating to address regulatory requirements and advance RNA therapeutics classes, such as RNAi treatment comparisons, RNA vaccine development, and gene delivery systems. These collaborative efforts are expected to drive innovation in the pharmacologic frontiers of RNA-based therapies, ultimately benefiting patients with various medical needs, including heart disease, cancer, pulmonary diseases, and neurodegenerative disorders. MicroRNAs, a type of non-coding RNA, are also gaining attention for their potential therapeutic applications, particularly in molecular diagnostics and therapeutic device development. As the field of RNA-based therapies continues to evolve, it is essential to compare and contrast various RNAi treatments and RNA vaccine types to optimize their efficacy and safety. Regulating authorities and government bodies play a crucial role in ensuring the safe and effective implementation of these novel therapies, as they navigate the complex regulatory landscape. Hence, the above factors will impede the growth of the market during the forecast period
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Alnylam Pharmaceuticals Inc. - The company offers RNA Based Therapeutic such as Givlaari, Oxlumo, Leqvio, and Amvuttra.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
RNA-based therapeutics have emerged as a promising area in the healthcare industry, with significant potential in treating various chronic conditions and rare diseases. The market for RNA-based therapies is witnessing growth in sectors such as Oncology pharmaceuticals, Infectious diseases, Neurodegenerative disorders, and the Geriatric population. RNA interference, a key technology in RNA therapeutics, is used for gene silencing and protein expression modulation. The regulatory requirements for RNA-based therapies are stringent due to their complex nature. Biopharmaceutical and biotechnological companies are investing in RNA therapeutics classes like RNAi treatment and RNA vaccine development. Research & academic laboratories and Hospitals & diagnostic laboratories are also adopting RNA-based therapies for medical studies and chronic illnesses treatment.
Furthermore, RNA therapeutics have applications in various therapeutic areas like cancer, heart disease, pulmonary diseases, and immunologic characteristics. Innovative products like RNA vaccines, gene delivery systems, and RNA-based therapeutic devices are under development for T-cell responses and B-cell responses modulation. The market for RNA-based therapies is diverse, with various RNA therapeutics classes, RNAi treatment comparison, and RNA vaccine development ongoing. MicroRNAs, a type of non-coding RNA, are gaining attention for their role in various therapeutic applications. Chronic conditions like chronic diseases and rare conditions are being targeted with RNA-based therapies. Regulating authorities and government bodies are also supporting the development and commercialization of RNA-based therapies to address unmet medical needs.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
208 |
|
Base year |
2023 |
|
Historic period |
2018 - 2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 5.54% |
|
Market growth 2024-2028 |
USD 1.26 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
5.12 |
|
Regional analysis |
Europe, North America, Asia, and Rest of World (ROW) |
|
Performing market contribution |
Europe at 36% |
|
Key countries |
US, China, Germany, UK, and Japan |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Alnylam Pharmaceuticals Inc., Arbutus Biopharma Corp., Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals Inc., Ascidian Therapeutics Inc, AstraZeneca Plc, Beam Therapeutics Inc., Benitec Biopharma Inc., Biogen Inc., BioNTech SE, BioSpace, Circular Genomics Inc., CureVac AG, Esperovax, Gennova Biopharmaceuticals Ltd, Ionis Pharmaceuticals Inc., Moderna Inc., Novartis AG, Novo Nordisk AS, Omega Therapeutics Inc., Sarepta Therapeutics Inc., Silence Therapeutics plc, and Tevard Biosciences |
|
Market dynamics |
Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for Market forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Technavio Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Type
9 Market Segmentation by Route of Administration
10 Customer Landscape
11 Geographic Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
With the growing adoption of AI across industries, Technavio has analyzed its impact on global RNA-based therapeutics market, centered on groundbreaking treatments like mRNA vaccines and RNA interference (RNAi) therapies, is advancing rapidly with the integration of Artificial Intelligence (AI). AI is driving innovation in drug discovery, personalized medicine, clinical trials, and patient monitoring. This analysis delves into AI's impact on the RNA-based therapeutics market, backed by data and real-world examples.
These insights, available exclusively through Technavio, provide an unparalleled significant impact of AI on the RNA-based therapeutics market, backed by real-world examples and data.
The report provides details of AI's impact on various segment
Learn more about how AI is transforming RNA-based Therapeutics Market - Buy Full Report Now
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
